OBJECTIVE: The presence of subclinical myocardial necrosis as a prodrome to longer-term adverse cardiac event risk has been debated. The debate has focused predominantly within patients with acute coronary syndrome, and on issues of troponin assay variability and accuracy of detection, rather than on the clinical significance of the presence of subclinical myocardial necrosis (ie, "troponin leak") within stable cardiac patients. Herein, we examine the relationship between different degrees of subclinical myocardial necrosis and long-term adverse clinical outcomes within a stable cardiac patient population with essentially normal renal function. METHODS AND RESULTS: Sequential consenting patients (N=3828; median creatinine clearance, 100 mL/min/1.73m(2)) undergoing elective diagnostic coronary angiography with cardiac troponin I (cTnI) levels below the diagnostic cut-off for defining myocardial infarction (<0.03 ng/mL) were evaluated. The relationship of subclinical myocardial necrosis with incident major adverse cardiovascular events (defined as any death, myocardial infarction, or stroke) over 3-year follow-up was examined. "Probable" (cTnI 0.001-0.008 ng/mL) and "definite" (cTnI 0.009-0.029 ng/mL) subclinical myocardial necrosis were observed frequently within the cohort (34% and 18%, respectively). A linear relationship was observed between the magnitude of subclinical myocardial necrosis and risk of 3-year incident major adverse cardiovascular events, particularly in those with cTnI 0.009 ng/mL or higher (hazard ratio, 3.00; 95% confidence interval, 2.4-3.8), even after adjustment for traditional risk factors, C-reactive protein, and creatinine clearance. The presence of subclinical myocardial necrosis was associated with elevations in acute phase proteins (C-reactive protein, ceruloplasmin; P<0.01 each) and reduction in systemic antioxidant enzyme activities (arylesterase; P<0.01) but showed no significant associations with multiple specific measures of oxidant stress, and showed borderline associations with myeloperoxidase, a marker of leukocyte activation. CONCLUSIONS: In stable cardiology patients, prodromal subclinical myocardial necrosis is associated with substantially higher long-term risk for major adverse cardiovascular events. The underlying mechanisms contributing to this minimal troponin leak phenomenon warrants further investigation.
OBJECTIVE: The presence of subclinical myocardial necrosis as a prodrome to longer-term adverse cardiac event risk has been debated. The debate has focused predominantly within patients with acute coronary syndrome, and on issues of troponin assay variability and accuracy of detection, rather than on the clinical significance of the presence of subclinical myocardial necrosis (ie, "troponin leak") within stable cardiac patients. Herein, we examine the relationship between different degrees of subclinical myocardial necrosis and long-term adverse clinical outcomes within a stable cardiac patient population with essentially normal renal function. METHODS AND RESULTS: Sequential consenting patients (N=3828; median creatinine clearance, 100 mL/min/1.73m(2)) undergoing elective diagnostic coronary angiography with cardiac troponin I (cTnI) levels below the diagnostic cut-off for defining myocardial infarction (<0.03 ng/mL) were evaluated. The relationship of subclinical myocardial necrosis with incident major adverse cardiovascular events (defined as any death, myocardial infarction, or stroke) over 3-year follow-up was examined. "Probable" (cTnI 0.001-0.008 ng/mL) and "definite" (cTnI 0.009-0.029 ng/mL) subclinical myocardial necrosis were observed frequently within the cohort (34% and 18%, respectively). A linear relationship was observed between the magnitude of subclinical myocardial necrosis and risk of 3-year incident major adverse cardiovascular events, particularly in those with cTnI 0.009 ng/mL or higher (hazard ratio, 3.00; 95% confidence interval, 2.4-3.8), even after adjustment for traditional risk factors, C-reactive protein, and creatinine clearance. The presence of subclinical myocardial necrosis was associated with elevations in acute phase proteins (C-reactive protein, ceruloplasmin; P<0.01 each) and reduction in systemic antioxidant enzyme activities (arylesterase; P<0.01) but showed no significant associations with multiple specific measures of oxidant stress, and showed borderline associations with myeloperoxidase, a marker of leukocyte activation. CONCLUSIONS: In stable cardiology patients, prodromal subclinical myocardial necrosis is associated with substantially higher long-term risk for major adverse cardiovascular events. The underlying mechanisms contributing to this minimal troponin leak phenomenon warrants further investigation.
Authors: Mehdi H Shishehbor; Renliang Zhang; Hector Medina; Marie-Luise Brennan; Danielle M Brennan; Stephen G Ellis; Eric J Topol; Stanley L Hazen Journal: Free Radic Biol Med Date: 2006-09-08 Impact factor: 7.376
Authors: Nadia A Khan; Brenda R Hemmelgarn; Marcello Tonelli; Christopher R Thompson; Adeera Levin Journal: Circulation Date: 2005-11-15 Impact factor: 29.690
Authors: Torbjørn Omland; James A de Lemos; Marc S Sabatine; Costas A Christophi; Madeline Murguia Rice; Kathleen A Jablonski; Solve Tjora; Michael J Domanski; Bernard J Gersh; Jean L Rouleau; Marc A Pfeffer; Eugene Braunwald Journal: N Engl J Med Date: 2009-11-25 Impact factor: 91.245
Authors: Benjamin J Freda; W H Wilson Tang; Frederick Van Lente; W Franklin Peacock; Gary S Francis Journal: J Am Coll Cardiol Date: 2002-12-18 Impact factor: 24.094
Authors: Stephen J Nicholls; W H Wilson Tang; Danielle Brennan; Marie-Luise Brennan; Shirley Mann; Steven E Nissen; Stanley L Hazen Journal: Clin Chem Date: 2011-09-22 Impact factor: 8.327
Authors: Aslan T Turer; Tayo A Addo; Justin L Martin; Marc S Sabatine; Gregory D Lewis; Robert E Gerszten; Ellen C Keeley; Joaquin E Cigarroa; Richard A Lange; L David Hillis; James A de Lemos Journal: J Am Coll Cardiol Date: 2011-06-14 Impact factor: 24.094
Authors: Stephen J Nicholls; W H Wilson Tang; Heather Scoffone; Danielle M Brennan; Jaana Hartiala; Hooman Allayee; Stanley L Hazen Journal: J Lipid Res Date: 2010-07-02 Impact factor: 5.922
Authors: Carmel M Halley; Jason M Lappé; Anne C Cotleur; Kevin Shrestha; Allen G Borowski; Clara Pelfrey; Richard Ransohoff; W H Wilson Tang Journal: J Card Fail Date: 2011-02-26 Impact factor: 5.712
Authors: Wei Li; David Kennedy; Zhili Shao; Xi Wang; Andre Klaassen Kamdar; Malory Weber; Kayla Mislick; Kathryn Kiefer; Rommel Morales; Brendan Agatisa-Boyle; Diana M Shih; Srinivasa T Reddy; Christine S Moravec; W H Wilson Tang Journal: Free Radic Biol Med Date: 2018-05-02 Impact factor: 7.376
Authors: Macy M S Lui; H F Tse; Judith C W Mak; David C L Lam; Carmen W S Chan; Peony W C Chong; Mary S M Ip Journal: J Clin Sleep Med Date: 2018-11-15 Impact factor: 4.062
Authors: David J Kennedy; W H Wilson Tang; Yiying Fan; Yuping Wu; Shirley Mann; Michael Pepoy; Stanley L Hazen Journal: J Am Heart Assoc Date: 2013-04-04 Impact factor: 5.501
Authors: Nicole Nigro; Karin Wildi; Christian Mueller; Philipp Schuetz; Beat Mueller; Felix Fluri; Mirjam Christ-Crain; Mira Katan Journal: PLoS One Date: 2014-07-29 Impact factor: 3.240